| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 165 | 2026 | 969 | 29.030 |
Why?
|
| Liver Neoplasms | 169 | 2026 | 1362 | 25.740 |
Why?
|
| Barrett Esophagus | 95 | 2026 | 349 | 21.040 |
Why?
|
| Liver Cirrhosis | 95 | 2026 | 898 | 14.370 |
Why?
|
| Esophageal Neoplasms | 63 | 2026 | 383 | 12.210 |
Why?
|
| Gastroesophageal Reflux | 66 | 2021 | 323 | 10.660 |
Why?
|
| Hepatitis C, Chronic | 52 | 2025 | 356 | 10.450 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 46 | 2025 | 402 | 10.060 |
Why?
|
| Hepatitis C | 57 | 2026 | 376 | 9.860 |
Why?
|
| Adenocarcinoma | 55 | 2025 | 964 | 8.180 |
Why?
|
| Helicobacter Infections | 44 | 2025 | 1307 | 6.940 |
Why?
|
| Veterans | 83 | 2025 | 1753 | 6.600 |
Why?
|
| Stomach Neoplasms | 30 | 2026 | 567 | 5.970 |
Why?
|
| Helicobacter pylori | 37 | 2025 | 1367 | 5.830 |
Why?
|
| Middle Aged | 337 | 2026 | 28337 | 5.540 |
Why?
|
| Early Detection of Cancer | 26 | 2026 | 414 | 5.410 |
Why?
|
| Proton Pump Inhibitors | 28 | 2025 | 276 | 5.320 |
Why?
|
| Gastroenterology | 22 | 2026 | 223 | 5.270 |
Why?
|
| Risk Factors | 195 | 2026 | 10938 | 5.220 |
Why?
|
| alpha-Fetoproteins | 21 | 2025 | 126 | 5.210 |
Why?
|
| Antiviral Agents | 40 | 2025 | 800 | 5.140 |
Why?
|
| United States | 227 | 2026 | 11837 | 4.900 |
Why?
|
| Humans | 619 | 2026 | 130262 | 4.850 |
Why?
|
| Aged | 262 | 2026 | 20840 | 4.800 |
Why?
|
| Incidence | 111 | 2026 | 3315 | 4.610 |
Why?
|
| Male | 383 | 2026 | 64355 | 4.220 |
Why?
|
| Precancerous Conditions | 18 | 2025 | 280 | 4.140 |
Why?
|
| Female | 362 | 2026 | 70269 | 3.750 |
Why?
|
| Endoscopy, Digestive System | 22 | 2025 | 151 | 3.580 |
Why?
|
| Liver Diseases | 18 | 2020 | 379 | 3.460 |
Why?
|
| Hepatitis B, Chronic | 16 | 2022 | 83 | 3.430 |
Why?
|
| Colorectal Neoplasms | 22 | 2024 | 615 | 3.360 |
Why?
|
| Colonoscopy | 16 | 2025 | 240 | 3.250 |
Why?
|
| Esophagus | 17 | 2017 | 231 | 3.220 |
Why?
|
| Obesity | 44 | 2024 | 2381 | 3.200 |
Why?
|
| Case-Control Studies | 69 | 2026 | 3358 | 2.900 |
Why?
|
| Mass Screening | 22 | 2021 | 808 | 2.760 |
Why?
|
| Cholangiocarcinoma | 16 | 2019 | 125 | 2.710 |
Why?
|
| Risk Assessment | 60 | 2026 | 3667 | 2.670 |
Why?
|
| Adult | 181 | 2026 | 31097 | 2.670 |
Why?
|
| Cohort Studies | 79 | 2025 | 5046 | 2.660 |
Why?
|
| Prevalence | 64 | 2026 | 2686 | 2.640 |
Why?
|
| Inflammatory Bowel Diseases | 14 | 2023 | 323 | 2.620 |
Why?
|
| United States Department of Veterans Affairs | 37 | 2024 | 710 | 2.420 |
Why?
|
| Population Surveillance | 17 | 2022 | 393 | 2.400 |
Why?
|
| Retrospective Studies | 127 | 2026 | 17500 | 2.390 |
Why?
|
| Hepacivirus | 18 | 2022 | 271 | 2.370 |
Why?
|
| Esophagoscopy | 20 | 2025 | 173 | 2.310 |
Why?
|
| Alcohol Drinking | 12 | 2024 | 337 | 2.250 |
Why?
|
| Bile Duct Neoplasms | 15 | 2025 | 134 | 2.250 |
Why?
|
| Colitis, Ulcerative | 11 | 2023 | 208 | 2.240 |
Why?
|
| Aged, 80 and over | 80 | 2024 | 6781 | 2.240 |
Why?
|
| Biomarkers, Tumor | 16 | 2026 | 1583 | 2.210 |
Why?
|
| Chemoprevention | 5 | 2020 | 49 | 2.180 |
Why?
|
| Cross-Sectional Studies | 59 | 2025 | 3791 | 2.170 |
Why?
|
| Logistic Models | 45 | 2026 | 1799 | 2.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2019 | 748 | 2.070 |
Why?
|
| Hepatitis B | 18 | 2021 | 170 | 2.050 |
Why?
|
| Irritable Bowel Syndrome | 7 | 2021 | 216 | 2.050 |
Why?
|
| Endoscopy, Gastrointestinal | 16 | 2023 | 226 | 2.000 |
Why?
|
| Pancreatic Neoplasms | 11 | 2023 | 732 | 1.990 |
Why?
|
| Crohn Disease | 11 | 2023 | 287 | 1.970 |
Why?
|
| Primary Health Care | 11 | 2025 | 768 | 1.850 |
Why?
|
| Prospective Studies | 42 | 2025 | 6436 | 1.820 |
Why?
|
| Gastritis | 9 | 2024 | 372 | 1.810 |
Why?
|
| Algorithms | 18 | 2026 | 1660 | 1.670 |
Why?
|
| Liver Diseases, Alcoholic | 5 | 2023 | 61 | 1.620 |
Why?
|
| Gastrointestinal Diseases | 9 | 2023 | 337 | 1.590 |
Why?
|
| Gastric Mucosa | 11 | 2026 | 491 | 1.580 |
Why?
|
| Hepatitis, Viral, Human | 7 | 2020 | 44 | 1.580 |
Why?
|
| Metaplasia | 16 | 2024 | 215 | 1.570 |
Why?
|
| Alanine Transaminase | 12 | 2024 | 154 | 1.570 |
Why?
|
| SEER Program | 28 | 2024 | 207 | 1.570 |
Why?
|
| Bile Ducts, Intrahepatic | 13 | 2019 | 103 | 1.550 |
Why?
|
| Fatty Liver | 8 | 2026 | 218 | 1.530 |
Why?
|
| Diet | 10 | 2025 | 1100 | 1.530 |
Why?
|
| Hospitals, Veterans | 17 | 2019 | 340 | 1.520 |
Why?
|
| Tenofovir | 4 | 2022 | 25 | 1.510 |
Why?
|
| Guanine | 4 | 2022 | 58 | 1.490 |
Why?
|
| Body Mass Index | 22 | 2024 | 1675 | 1.480 |
Why?
|
| Histamine H2 Antagonists | 9 | 2019 | 47 | 1.480 |
Why?
|
| Disease Progression | 23 | 2025 | 2193 | 1.480 |
Why?
|
| Aspirin | 4 | 2020 | 214 | 1.480 |
Why?
|
| Age Factors | 38 | 2020 | 2826 | 1.470 |
Why?
|
| Texas | 31 | 2025 | 3639 | 1.450 |
Why?
|
| Dyspepsia | 10 | 2022 | 108 | 1.440 |
Why?
|
| Anti-Ulcer Agents | 7 | 2009 | 110 | 1.420 |
Why?
|
| Predictive Value of Tests | 25 | 2026 | 2290 | 1.420 |
Why?
|
| Referral and Consultation | 8 | 2025 | 555 | 1.390 |
Why?
|
| Proportional Hazards Models | 27 | 2024 | 1389 | 1.380 |
Why?
|
| Odds Ratio | 30 | 2021 | 1210 | 1.370 |
Why?
|
| Periodicals as Topic | 7 | 2017 | 182 | 1.350 |
Why?
|
| Cardia | 9 | 2012 | 25 | 1.340 |
Why?
|
| Prognosis | 41 | 2024 | 4854 | 1.320 |
Why?
|
| Sensitivity and Specificity | 23 | 2026 | 2087 | 1.320 |
Why?
|
| Writing | 4 | 2016 | 59 | 1.300 |
Why?
|
| Diabetes Complications | 7 | 2020 | 197 | 1.290 |
Why?
|
| Hepatitis B virus | 7 | 2022 | 131 | 1.290 |
Why?
|
| Follow-Up Studies | 35 | 2021 | 5163 | 1.260 |
Why?
|
| Registries | 28 | 2025 | 1605 | 1.260 |
Why?
|
| Veterans Health | 7 | 2020 | 170 | 1.260 |
Why?
|
| Age Distribution | 25 | 2022 | 422 | 1.250 |
Why?
|
| Critical Pathways | 3 | 2026 | 77 | 1.240 |
Why?
|
| Medicare | 14 | 2023 | 436 | 1.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 11 | 2018 | 291 | 1.200 |
Why?
|
| Practice Guidelines as Topic | 12 | 2024 | 1288 | 1.170 |
Why?
|
| Endoscopy | 8 | 2024 | 267 | 1.160 |
Why?
|
| Multivariate Analysis | 25 | 2018 | 1374 | 1.150 |
Why?
|
| Electronic Health Records | 10 | 2025 | 814 | 1.130 |
Why?
|
| Biomarkers | 15 | 2024 | 3379 | 1.120 |
Why?
|
| Patient Compliance | 8 | 2018 | 460 | 1.110 |
Why?
|
| Quality of Life | 13 | 2019 | 2078 | 1.100 |
Why?
|
| Decision Support Techniques | 6 | 2021 | 293 | 1.080 |
Why?
|
| Esophageal Diseases | 5 | 2013 | 32 | 1.070 |
Why?
|
| Time Factors | 32 | 2021 | 6197 | 1.050 |
Why?
|
| Phospholipases A2, Calcium-Independent | 3 | 2024 | 19 | 1.050 |
Why?
|
| Esophagitis | 12 | 2013 | 36 | 1.040 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2015 | 81 | 1.030 |
Why?
|
| Interferons | 3 | 2025 | 135 | 1.030 |
Why?
|
| Stomach | 7 | 2022 | 269 | 1.010 |
Why?
|
| Liver Transplantation | 11 | 2025 | 1127 | 1.000 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2018 | 741 | 0.990 |
Why?
|
| Colon | 9 | 2025 | 359 | 0.990 |
Why?
|
| Severity of Illness Index | 28 | 2025 | 3031 | 0.990 |
Why?
|
| Sustained Virologic Response | 5 | 2019 | 46 | 0.990 |
Why?
|
| Smoking | 10 | 2023 | 928 | 0.980 |
Why?
|
| Metabolic Syndrome | 9 | 2022 | 364 | 0.980 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2026 | 2823 | 0.980 |
Why?
|
| Protein Precursors | 2 | 2024 | 139 | 0.970 |
Why?
|
| Sex Factors | 20 | 2019 | 1339 | 0.970 |
Why?
|
| Survival Rate | 25 | 2020 | 2110 | 0.970 |
Why?
|
| Quality Indicators, Health Care | 8 | 2021 | 237 | 0.960 |
Why?
|
| Cost of Illness | 9 | 2026 | 293 | 0.940 |
Why?
|
| Hernia, Hiatal | 7 | 2014 | 55 | 0.930 |
Why?
|
| Polyps | 1 | 2026 | 40 | 0.910 |
Why?
|
| Sleep | 4 | 2025 | 366 | 0.910 |
Why?
|
| Global Health | 15 | 2021 | 633 | 0.900 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2018 | 129 | 0.900 |
Why?
|
| Risk | 13 | 2020 | 722 | 0.890 |
Why?
|
| Survival Analysis | 22 | 2018 | 1481 | 0.890 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2016 | 499 | 0.880 |
Why?
|
| Interleukins | 3 | 2015 | 121 | 0.880 |
Why?
|
| Genetic Loci | 2 | 2026 | 353 | 0.880 |
Why?
|
| Diagnostic Errors | 3 | 2017 | 342 | 0.860 |
Why?
|
| Biopsy | 21 | 2026 | 1241 | 0.860 |
Why?
|
| Drug Therapy, Combination | 10 | 2025 | 1166 | 0.850 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2026 | 146 | 0.830 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2014 | 773 | 0.820 |
Why?
|
| Gastrointestinal Microbiome | 9 | 2025 | 831 | 0.820 |
Why?
|
| Comorbidity | 23 | 2022 | 1582 | 0.810 |
Why?
|
| HIV Infections | 11 | 2017 | 2030 | 0.810 |
Why?
|
| Neoplasm Staging | 17 | 2022 | 1279 | 0.800 |
Why?
|
| Machine Learning | 2 | 2025 | 381 | 0.800 |
Why?
|
| Diet, Mediterranean | 1 | 2023 | 18 | 0.790 |
Why?
|
| Biomedical Research | 3 | 2021 | 561 | 0.780 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2026 | 206 | 0.780 |
Why?
|
| Comparative Effectiveness Research | 3 | 2012 | 70 | 0.780 |
Why?
|
| Esophagitis, Peptic | 7 | 2006 | 34 | 0.770 |
Why?
|
| Treatment Outcome | 41 | 2025 | 12830 | 0.760 |
Why?
|
| International Classification of Diseases | 5 | 2022 | 92 | 0.760 |
Why?
|
| Betacoronavirus | 3 | 2020 | 282 | 0.750 |
Why?
|
| Arsenic | 1 | 2023 | 48 | 0.750 |
Why?
|
| Anxiety | 3 | 2025 | 1007 | 0.740 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2026 | 3396 | 0.740 |
Why?
|
| Diabetes Mellitus | 7 | 2023 | 889 | 0.740 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 260 | 0.730 |
Why?
|
| Waist-Hip Ratio | 7 | 2015 | 53 | 0.720 |
Why?
|
| Diphosphonates | 2 | 2013 | 40 | 0.710 |
Why?
|
| Anti-Bacterial Agents | 8 | 2025 | 2563 | 0.700 |
Why?
|
| Digestive System Diseases | 3 | 2023 | 23 | 0.690 |
Why?
|
| Coffee | 4 | 2023 | 28 | 0.690 |
Why?
|
| Eosinophilic Esophagitis | 3 | 2013 | 78 | 0.680 |
Why?
|
| Leadership | 2 | 2021 | 244 | 0.680 |
Why?
|
| Transition to Adult Care | 2 | 2020 | 134 | 0.680 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 351 | 0.670 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 363 | 0.670 |
Why?
|
| Ascites | 3 | 2016 | 98 | 0.660 |
Why?
|
| Medical Records Systems, Computerized | 4 | 2009 | 138 | 0.660 |
Why?
|
| Publishing | 3 | 2016 | 108 | 0.660 |
Why?
|
| Esophageal Stenosis | 4 | 2007 | 45 | 0.650 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 306 | 0.650 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 776 | 0.650 |
Why?
|
| Peptic Ulcer | 4 | 2009 | 149 | 0.650 |
Why?
|
| Gastroscopy | 6 | 2026 | 98 | 0.640 |
Why?
|
| Awards and Prizes | 1 | 2021 | 62 | 0.640 |
Why?
|
| Young Adult | 25 | 2024 | 9993 | 0.640 |
Why?
|
| Peer Review, Research | 3 | 2016 | 46 | 0.640 |
Why?
|
| Life Style | 6 | 2020 | 445 | 0.640 |
Why?
|
| Natural Language Processing | 4 | 2022 | 74 | 0.640 |
Why?
|
| Mexican Americans | 2 | 2018 | 162 | 0.640 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2025 | 1268 | 0.630 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2018 | 2062 | 0.630 |
Why?
|
| Hospitalization | 10 | 2018 | 1926 | 0.630 |
Why?
|
| Intestinal Mucosa | 8 | 2025 | 760 | 0.630 |
Why?
|
| Delayed Diagnosis | 2 | 2012 | 130 | 0.630 |
Why?
|
| Caffeine | 2 | 2023 | 66 | 0.620 |
Why?
|
| Phenylurea Compounds | 3 | 2019 | 56 | 0.620 |
Why?
|
| Fundoplication | 4 | 2005 | 69 | 0.620 |
Why?
|
| Surveys and Questionnaires | 20 | 2022 | 4021 | 0.620 |
Why?
|
| Duodenum | 2 | 2020 | 112 | 0.620 |
Why?
|
| Multiple Sclerosis | 1 | 2023 | 394 | 0.620 |
Why?
|
| Databases, Factual | 14 | 2021 | 1223 | 0.610 |
Why?
|
| Cryoglobulinemia | 2 | 2019 | 10 | 0.610 |
Why?
|
| Patient Selection | 6 | 2020 | 719 | 0.610 |
Why?
|
| Program Development | 1 | 2020 | 181 | 0.610 |
Why?
|
| Sex Distribution | 12 | 2017 | 318 | 0.600 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 191 | 0.600 |
Why?
|
| Niacinamide | 2 | 2017 | 31 | 0.600 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 2019 | 5 | 0.600 |
Why?
|
| Coinfection | 6 | 2017 | 186 | 0.590 |
Why?
|
| Lichen Planus | 1 | 2019 | 9 | 0.590 |
Why?
|
| Eosinophilia | 3 | 2020 | 110 | 0.590 |
Why?
|
| Quality Improvement | 3 | 2025 | 705 | 0.580 |
Why?
|
| Patient Care Team | 2 | 2020 | 558 | 0.580 |
Why?
|
| Inflammation | 5 | 2020 | 1481 | 0.580 |
Why?
|
| Adolescent | 39 | 2020 | 20711 | 0.580 |
Why?
|
| Anthropometry | 3 | 2017 | 187 | 0.570 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 75 | 0.570 |
Why?
|
| Pyridines | 3 | 2019 | 257 | 0.570 |
Why?
|
| Models, Statistical | 3 | 2016 | 481 | 0.560 |
Why?
|
| Hypnosis | 1 | 2018 | 9 | 0.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2024 | 1442 | 0.560 |
Why?
|
| Overweight | 3 | 2023 | 376 | 0.560 |
Why?
|
| Dyslipidemias | 3 | 2020 | 252 | 0.560 |
Why?
|
| Epidemics | 4 | 2021 | 57 | 0.540 |
Why?
|
| Hyperplasia | 3 | 2022 | 189 | 0.540 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 36 | 0.540 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2008 | 255 | 0.540 |
Why?
|
| Mindfulness | 1 | 2018 | 33 | 0.530 |
Why?
|
| Drug Prescriptions | 5 | 2014 | 228 | 0.530 |
Why?
|
| Adipokines | 3 | 2018 | 118 | 0.530 |
Why?
|
| Gastrointestinal Agents | 3 | 2017 | 62 | 0.530 |
Why?
|
| Cytokines | 2 | 2013 | 1341 | 0.530 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 396 | 0.520 |
Why?
|
| Feeding Behavior | 2 | 2015 | 708 | 0.520 |
Why?
|
| Bacteriological Techniques | 1 | 2018 | 87 | 0.520 |
Why?
|
| Proton Pumps | 2 | 2007 | 12 | 0.520 |
Why?
|
| Vegetables | 3 | 2018 | 266 | 0.520 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2015 | 65 | 0.510 |
Why?
|
| Health Status | 5 | 2016 | 370 | 0.510 |
Why?
|
| Evidence-Based Medicine | 5 | 2021 | 641 | 0.510 |
Why?
|
| Guideline Adherence | 4 | 2014 | 389 | 0.510 |
Why?
|
| Platelet Count | 4 | 2024 | 136 | 0.500 |
Why?
|
| Obesity, Abdominal | 3 | 2014 | 39 | 0.500 |
Why?
|
| Liver Cirrhosis, Alcoholic | 6 | 2023 | 38 | 0.500 |
Why?
|
| Genotype | 13 | 2022 | 2590 | 0.500 |
Why?
|
| Celiac Disease | 2 | 2016 | 73 | 0.500 |
Why?
|
| Editorial Policies | 3 | 2017 | 50 | 0.500 |
Why?
|
| Dietary Carbohydrates | 3 | 2020 | 106 | 0.490 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2017 | 89 | 0.490 |
Why?
|
| Quality of Health Care | 4 | 2014 | 408 | 0.490 |
Why?
|
| Research Support as Topic | 1 | 2016 | 62 | 0.490 |
Why?
|
| Leptin | 3 | 2018 | 215 | 0.490 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 1594 | 0.490 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2020 | 636 | 0.490 |
Why?
|
| Meat | 2 | 2013 | 44 | 0.480 |
Why?
|
| Patient Readmission | 2 | 2019 | 433 | 0.480 |
Why?
|
| Cause of Death | 5 | 2019 | 502 | 0.480 |
Why?
|
| Ticlopidine | 1 | 2015 | 28 | 0.470 |
Why?
|
| Health Status Disparities | 4 | 2024 | 277 | 0.470 |
Why?
|
| Palliative Care | 3 | 2018 | 443 | 0.470 |
Why?
|
| Behavior Therapy | 2 | 2015 | 271 | 0.470 |
Why?
|
| Communication | 1 | 2020 | 539 | 0.470 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 10 | 0.460 |
Why?
|
| Medically Uninsured | 2 | 2015 | 79 | 0.460 |
Why?
|
| Medical Audit | 2 | 2012 | 97 | 0.450 |
Why?
|
| Confidence Intervals | 10 | 2013 | 269 | 0.450 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2018 | 227 | 0.440 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 130 | 0.440 |
Why?
|
| Prothrombin | 3 | 2024 | 23 | 0.440 |
Why?
|
| Body Fat Distribution | 2 | 2012 | 30 | 0.440 |
Why?
|
| Quality Assurance, Health Care | 3 | 2010 | 205 | 0.430 |
Why?
|
| Adiposity | 2 | 2014 | 208 | 0.430 |
Why?
|
| Cost-Benefit Analysis | 8 | 2026 | 546 | 0.430 |
Why?
|
| Reproducibility of Results | 11 | 2024 | 2891 | 0.430 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 149 | 0.430 |
Why?
|
| Regression Analysis | 11 | 2017 | 759 | 0.420 |
Why?
|
| Ultrasonography | 7 | 2026 | 955 | 0.420 |
Why?
|
| Bile Ducts, Extrahepatic | 5 | 2019 | 20 | 0.420 |
Why?
|
| Acyltransferases | 3 | 2024 | 63 | 0.420 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 315 | 0.420 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 121 | 0.420 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2014 | 23 | 0.410 |
Why?
|
| Hepatitis B Vaccines | 2 | 2011 | 49 | 0.410 |
Why?
|
| Proline | 1 | 2014 | 77 | 0.400 |
Why?
|
| Oligopeptides | 1 | 2014 | 104 | 0.400 |
Why?
|
| Demography | 6 | 2021 | 236 | 0.400 |
Why?
|
| Glycation End Products, Advanced | 1 | 2013 | 26 | 0.400 |
Why?
|
| Stomach Diseases | 2 | 2020 | 56 | 0.400 |
Why?
|
| Preventive Health Services | 2 | 2013 | 58 | 0.400 |
Why?
|
| Viremia | 2 | 2011 | 130 | 0.400 |
Why?
|
| Information Dissemination | 1 | 2016 | 195 | 0.400 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 428 | 0.400 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 46 | 0.390 |
Why?
|
| Osteoporosis | 2 | 2013 | 134 | 0.390 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2013 | 37 | 0.390 |
Why?
|
| Outpatients | 2 | 2013 | 264 | 0.390 |
Why?
|
| Air Pollutants, Occupational | 1 | 2013 | 24 | 0.390 |
Why?
|
| Health Planning Guidelines | 1 | 2013 | 33 | 0.390 |
Why?
|
| Hepatitis | 1 | 2013 | 56 | 0.380 |
Why?
|
| Research Design | 5 | 2018 | 714 | 0.380 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 56 | 0.380 |
Why?
|
| Hemochromatosis | 3 | 2022 | 39 | 0.380 |
Why?
|
| Aspartate Aminotransferases | 4 | 2016 | 80 | 0.380 |
Why?
|
| Fructose | 1 | 2013 | 60 | 0.380 |
Why?
|
| Subcutaneous Fat | 1 | 2013 | 32 | 0.380 |
Why?
|
| Health Services Research | 3 | 2012 | 178 | 0.380 |
Why?
|
| Colonic Diseases, Functional | 2 | 2003 | 25 | 0.380 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 61 | 0.380 |
Why?
|
| Mortality | 5 | 2020 | 259 | 0.380 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2016 | 72 | 0.370 |
Why?
|
| Chi-Square Distribution | 10 | 2014 | 564 | 0.370 |
Why?
|
| Viral Hepatitis Vaccines | 2 | 2012 | 19 | 0.370 |
Why?
|
| Leukopenia | 1 | 2012 | 43 | 0.370 |
Why?
|
| Finasteride | 1 | 2012 | 12 | 0.370 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 9 | 0.370 |
Why?
|
| Occupational Diseases | 1 | 2013 | 77 | 0.370 |
Why?
|
| Socioeconomic Factors | 10 | 2024 | 897 | 0.370 |
Why?
|
| Watchful Waiting | 4 | 2021 | 73 | 0.370 |
Why?
|
| Anus Neoplasms | 2 | 2013 | 40 | 0.360 |
Why?
|
| Triglycerides | 2 | 2019 | 604 | 0.360 |
Why?
|
| Narcotics | 1 | 2012 | 59 | 0.360 |
Why?
|
| Bacteria | 6 | 2025 | 519 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 917 | 0.360 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 85 | 0.360 |
Why?
|
| Colonic Polyps | 2 | 2024 | 81 | 0.350 |
Why?
|
| Methadone | 1 | 2012 | 127 | 0.350 |
Why?
|
| Serum | 1 | 2011 | 42 | 0.350 |
Why?
|
| Occult Blood | 3 | 2024 | 31 | 0.350 |
Why?
|
| Occupational Exposure | 1 | 2013 | 137 | 0.350 |
Why?
|
| Lipase | 3 | 2024 | 88 | 0.350 |
Why?
|
| Tuberculosis | 1 | 2017 | 554 | 0.350 |
Why?
|
| Serum Albumin | 2 | 2024 | 101 | 0.340 |
Why?
|
| Epidemiologic Studies | 2 | 2012 | 40 | 0.340 |
Why?
|
| Asia | 6 | 2021 | 125 | 0.340 |
Why?
|
| Papillomaviridae | 1 | 2012 | 177 | 0.340 |
Why?
|
| Enterochromaffin-like Cells | 1 | 2011 | 3 | 0.340 |
Why?
|
| Klatskin Tumor | 2 | 2025 | 10 | 0.340 |
Why?
|
| Vitamin D | 1 | 2013 | 198 | 0.340 |
Why?
|
| Benzofurans | 3 | 2022 | 34 | 0.340 |
Why?
|
| Quinoxalines | 3 | 2022 | 39 | 0.340 |
Why?
|
| Hepatitis A Vaccines | 1 | 2010 | 9 | 0.340 |
Why?
|
| Medical History Taking | 2 | 2016 | 107 | 0.340 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2005 | 135 | 0.330 |
Why?
|
| Gastrectomy | 3 | 2007 | 104 | 0.330 |
Why?
|
| Amitriptyline | 3 | 2017 | 27 | 0.330 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 24 | 0.330 |
Why?
|
| Health Services Accessibility | 4 | 2014 | 694 | 0.330 |
Why?
|
| ROC Curve | 7 | 2021 | 608 | 0.330 |
Why?
|
| Citalopram | 3 | 2017 | 28 | 0.330 |
Why?
|
| Folic Acid | 1 | 2013 | 269 | 0.330 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 589 | 0.330 |
Why?
|
| Anti-Retroviral Agents | 2 | 2013 | 154 | 0.330 |
Why?
|
| Gene Expression Profiling | 2 | 2009 | 1807 | 0.330 |
Why?
|
| Antidepressive Agents, Tricyclic | 4 | 2017 | 28 | 0.330 |
Why?
|
| Liver Function Tests | 5 | 2020 | 96 | 0.320 |
Why?
|
| Antioxidants | 1 | 2013 | 334 | 0.320 |
Why?
|
| Contraceptives, Oral | 2 | 2007 | 37 | 0.320 |
Why?
|
| Hormone Replacement Therapy | 3 | 2020 | 187 | 0.320 |
Why?
|
| Endemic Diseases | 1 | 2010 | 60 | 0.320 |
Why?
|
| Asthma | 2 | 2010 | 916 | 0.320 |
Why?
|
| Health Facilities | 1 | 2010 | 66 | 0.320 |
Why?
|
| Gastritis, Atrophic | 1 | 2011 | 61 | 0.320 |
Why?
|
| Age of Onset | 6 | 2016 | 595 | 0.320 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 511 | 0.320 |
Why?
|
| Myocardial Infarction | 2 | 2015 | 998 | 0.310 |
Why?
|
| History, 21st Century | 2 | 2021 | 256 | 0.310 |
Why?
|
| Omeprazole | 5 | 2018 | 101 | 0.310 |
Why?
|
| Postmenopause | 5 | 2019 | 135 | 0.310 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2013 | 238 | 0.310 |
Why?
|
| Interferon-alpha | 4 | 2011 | 238 | 0.310 |
Why?
|
| Esophagogastric Junction | 4 | 2008 | 35 | 0.310 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 226 | 0.310 |
Why?
|
| Probability | 7 | 2007 | 306 | 0.310 |
Why?
|
| Databases as Topic | 3 | 2007 | 73 | 0.310 |
Why?
|
| Imidazoles | 3 | 2022 | 220 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2018 | 636 | 0.300 |
Why?
|
| Depression | 4 | 2020 | 1315 | 0.300 |
Why?
|
| History, 20th Century | 2 | 2021 | 360 | 0.300 |
Why?
|
| Sex Offenses | 1 | 2010 | 52 | 0.300 |
Why?
|
| Membrane Proteins | 4 | 2024 | 1589 | 0.300 |
Why?
|
| Child | 23 | 2019 | 26079 | 0.300 |
Why?
|
| Ascitic Fluid | 1 | 2009 | 28 | 0.300 |
Why?
|
| Genome-Wide Association Study | 3 | 2026 | 1822 | 0.300 |
Why?
|
| Chemoembolization, Therapeutic | 4 | 2019 | 23 | 0.300 |
Why?
|
| Family Health | 1 | 2010 | 241 | 0.300 |
Why?
|
| Metformin | 2 | 2021 | 171 | 0.300 |
Why?
|
| Microdissection | 1 | 2009 | 13 | 0.290 |
Why?
|
| Reference Values | 5 | 2009 | 677 | 0.290 |
Why?
|
| Physicians | 1 | 2016 | 634 | 0.290 |
Why?
|
| Protective Factors | 3 | 2018 | 92 | 0.290 |
Why?
|
| Adipose Tissue | 2 | 2017 | 499 | 0.290 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 407 | 0.290 |
Why?
|
| Self Report | 4 | 2018 | 555 | 0.290 |
Why?
|
| Child, Preschool | 18 | 2018 | 14939 | 0.290 |
Why?
|
| Liver | 8 | 2020 | 1788 | 0.280 |
Why?
|
| Lasers | 1 | 2009 | 111 | 0.280 |
Why?
|
| Inpatients | 1 | 2013 | 558 | 0.280 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 657 | 0.280 |
Why?
|
| Disease Management | 3 | 2018 | 556 | 0.280 |
Why?
|
| Antacids | 2 | 2014 | 28 | 0.280 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 1121 | 0.280 |
Why?
|
| Linear Models | 6 | 2015 | 686 | 0.280 |
Why?
|
| Manuscripts as Topic | 1 | 2008 | 1 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 3746 | 0.280 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2020 | 73 | 0.270 |
Why?
|
| Hepatectomy | 2 | 2009 | 131 | 0.270 |
Why?
|
| Dietary Fiber | 4 | 2020 | 77 | 0.270 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 383 | 0.270 |
Why?
|
| Nutrition Surveys | 5 | 2019 | 327 | 0.270 |
Why?
|
| Combined Modality Therapy | 6 | 2014 | 1217 | 0.270 |
Why?
|
| Immunization Programs | 1 | 2008 | 69 | 0.270 |
Why?
|
| Motor Activity | 1 | 2010 | 492 | 0.270 |
Why?
|
| Recurrence | 8 | 2018 | 1470 | 0.260 |
Why?
|
| Ablation Techniques | 3 | 2021 | 30 | 0.260 |
Why?
|
| Keratins | 1 | 2007 | 49 | 0.260 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2018 | 31 | 0.260 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 147 | 0.250 |
Why?
|
| End Stage Liver Disease | 3 | 2025 | 192 | 0.250 |
Why?
|
| Exercise | 3 | 2025 | 863 | 0.250 |
Why?
|
| Abdominal Pain | 1 | 2009 | 315 | 0.250 |
Why?
|
| Intestines | 2 | 2021 | 587 | 0.250 |
Why?
|
| Authorship | 1 | 2006 | 30 | 0.250 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 158 | 0.250 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 391 | 0.240 |
Why?
|
| RNA, Ribosomal, 16S | 6 | 2025 | 373 | 0.240 |
Why?
|
| Alcohol Abstinence | 2 | 2017 | 15 | 0.240 |
Why?
|
| Nonprescription Drugs | 1 | 2007 | 56 | 0.240 |
Why?
|
| Testosterone | 1 | 2011 | 531 | 0.240 |
Why?
|
| Statistics, Nonparametric | 4 | 2013 | 425 | 0.240 |
Why?
|
| Pancreatectomy | 1 | 2007 | 145 | 0.240 |
Why?
|
| Adenomatous Polyps | 1 | 2026 | 15 | 0.240 |
Why?
|
| Delivery of Health Care | 4 | 2023 | 684 | 0.240 |
Why?
|
| Emigrants and Immigrants | 2 | 2025 | 169 | 0.230 |
Why?
|
| Infant | 14 | 2018 | 13230 | 0.230 |
Why?
|
| Fruit | 3 | 2020 | 228 | 0.230 |
Why?
|
| Alcoholism | 4 | 2015 | 243 | 0.230 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 72 | 0.230 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 43 | 0.230 |
Why?
|
| Embolization, Therapeutic | 3 | 2015 | 224 | 0.230 |
Why?
|
| Data Collection | 3 | 2013 | 368 | 0.230 |
Why?
|
| Stomach Ulcer | 1 | 2026 | 95 | 0.230 |
Why?
|
| Longitudinal Studies | 5 | 2026 | 1486 | 0.230 |
Why?
|
| Liver Failure | 2 | 2005 | 99 | 0.230 |
Why?
|
| Depressive Disorder | 2 | 2010 | 460 | 0.230 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 2 | 2017 | 25 | 0.230 |
Why?
|
| Australia | 4 | 2021 | 171 | 0.220 |
Why?
|
| Observational Studies as Topic | 2 | 2017 | 101 | 0.220 |
Why?
|
| Microbiota | 2 | 2020 | 436 | 0.220 |
Why?
|
| Europe | 5 | 2021 | 366 | 0.220 |
Why?
|
| Dairy Products | 1 | 2025 | 42 | 0.220 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2005 | 22 | 0.220 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 84 | 0.220 |
Why?
|
| Catheter Ablation | 3 | 2014 | 321 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 1612 | 0.220 |
Why?
|
| Linkage Disequilibrium | 1 | 2025 | 316 | 0.210 |
Why?
|
| Chronic Disease | 5 | 2018 | 1236 | 0.210 |
Why?
|
| Sex Characteristics | 2 | 2023 | 323 | 0.210 |
Why?
|
| Pandemics | 3 | 2020 | 1160 | 0.210 |
Why?
|
| Geography | 2 | 2020 | 114 | 0.210 |
Why?
|
| Epidemiologic Methods | 4 | 2011 | 91 | 0.210 |
Why?
|
| Hypertension | 3 | 2022 | 1348 | 0.200 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 78 | 0.200 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 95 | 0.200 |
Why?
|
| Gastroenterologists | 1 | 2023 | 13 | 0.200 |
Why?
|
| Stress, Psychological | 1 | 2008 | 539 | 0.200 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 416 | 0.200 |
Why?
|
| DNA, Viral | 3 | 2018 | 452 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 995 | 0.200 |
Why?
|
| Research | 2 | 2017 | 265 | 0.200 |
Why?
|
| Adenoma | 1 | 2024 | 143 | 0.190 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2022 | 110 | 0.190 |
Why?
|
| North America | 4 | 2024 | 257 | 0.190 |
Why?
|
| Propensity Score | 2 | 2016 | 271 | 0.190 |
Why?
|
| Heartburn | 4 | 2021 | 17 | 0.190 |
Why?
|
| Trans Fatty Acids | 1 | 2022 | 12 | 0.190 |
Why?
|
| Substance-Related Disorders | 2 | 2004 | 482 | 0.190 |
Why?
|
| Viral Load | 3 | 2013 | 407 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 1 | 2025 | 254 | 0.180 |
Why?
|
| Drug Costs | 1 | 2002 | 62 | 0.180 |
Why?
|
| Forecasting | 2 | 2020 | 350 | 0.180 |
Why?
|
| Health Surveys | 2 | 2013 | 255 | 0.180 |
Why?
|
| Phenotype | 4 | 2026 | 4465 | 0.180 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 155 | 0.180 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 1793 | 0.180 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2001 | 19 | 0.170 |
Why?
|
| Taiwan | 2 | 2018 | 38 | 0.170 |
Why?
|
| Hobbies | 1 | 2021 | 4 | 0.170 |
Why?
|
| Cathartics | 1 | 2021 | 29 | 0.170 |
Why?
|
| Laryngitis | 1 | 2001 | 7 | 0.170 |
Why?
|
| Minority Groups | 1 | 2023 | 258 | 0.170 |
Why?
|
| Sweden | 6 | 2017 | 37 | 0.170 |
Why?
|
| Cholecystectomy | 2 | 2012 | 57 | 0.170 |
Why?
|
| Respiratory Tract Diseases | 1 | 2001 | 81 | 0.170 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 151 | 0.170 |
Why?
|
| Feces | 3 | 2021 | 720 | 0.170 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2007 | 411 | 0.170 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 351 | 0.170 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 388 | 0.170 |
Why?
|
| Pyloric Antrum | 3 | 2007 | 62 | 0.170 |
Why?
|
| Trefoil Factor-2 | 1 | 2020 | 9 | 0.170 |
Why?
|
| Dietary Fats | 3 | 2022 | 275 | 0.170 |
Why?
|
| Tooth Loss | 1 | 2020 | 4 | 0.170 |
Why?
|
| Cell Degranulation | 1 | 2020 | 27 | 0.160 |
Why?
|
| Laryngeal Neoplasms | 1 | 2001 | 85 | 0.160 |
Why?
|
| Qualitative Research | 3 | 2014 | 701 | 0.160 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 31 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 899 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 33 | 0.160 |
Why?
|
| Genes, MHC Class I | 1 | 2000 | 11 | 0.160 |
Why?
|
| Needs Assessment | 1 | 2021 | 174 | 0.160 |
Why?
|
| Lansoprazole | 3 | 2007 | 26 | 0.160 |
Why?
|
| Social Class | 2 | 2015 | 209 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 2 | 2018 | 223 | 0.160 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 3 | 2007 | 30 | 0.160 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 39 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 498 | 0.150 |
Why?
|
| Likelihood Functions | 2 | 2010 | 115 | 0.150 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 88 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 170 | 0.150 |
Why?
|
| Eosinophils | 1 | 2020 | 119 | 0.150 |
Why?
|
| Observer Variation | 1 | 2020 | 309 | 0.150 |
Why?
|
| Electric Impedance | 2 | 2017 | 71 | 0.150 |
Why?
|
| Postoperative Care | 1 | 2001 | 294 | 0.150 |
Why?
|
| Mentoring | 1 | 2021 | 84 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2020 | 124 | 0.150 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1215 | 0.150 |
Why?
|
| Analysis of Variance | 3 | 2009 | 938 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1264 | 0.150 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 204 | 0.150 |
Why?
|
| Carbamazepine | 1 | 1999 | 40 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 2952 | 0.140 |
Why?
|
| Cholangitis | 1 | 1999 | 38 | 0.140 |
Why?
|
| Bias | 3 | 2008 | 146 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2020 | 228 | 0.140 |
Why?
|
| Awareness | 1 | 2019 | 80 | 0.140 |
Why?
|
| Societies, Medical | 2 | 2020 | 796 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2000 | 226 | 0.140 |
Why?
|
| Health Services Administration | 1 | 2018 | 7 | 0.140 |
Why?
|
| Capsule Endoscopy | 1 | 2018 | 15 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 296 | 0.140 |
Why?
|
| Genetic Counseling | 1 | 2000 | 237 | 0.140 |
Why?
|
| Decision Making | 3 | 2013 | 696 | 0.140 |
Why?
|
| Pancreatic Elastase | 1 | 2018 | 11 | 0.140 |
Why?
|
| Poisson Distribution | 3 | 2012 | 50 | 0.140 |
Why?
|
| Diet Records | 2 | 2020 | 69 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 65 | 0.140 |
Why?
|
| Edible Grain | 1 | 2018 | 42 | 0.140 |
Why?
|
| Drug Monitoring | 2 | 2012 | 288 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 58 | 0.130 |
Why?
|
| Costs and Cost Analysis | 3 | 2016 | 151 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2018 | 271 | 0.130 |
Why?
|
| Hospice Care | 1 | 2018 | 31 | 0.130 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 9 | 0.130 |
Why?
|
| Hospital Mortality | 2 | 2017 | 1059 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 1074 | 0.130 |
Why?
|
| Virus Activation | 1 | 2018 | 85 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 299 | 0.130 |
Why?
|
| Patient Participation | 1 | 2020 | 247 | 0.130 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2018 | 38 | 0.130 |
Why?
|
| United Kingdom | 2 | 2008 | 257 | 0.130 |
Why?
|
| Genetic Testing | 2 | 2015 | 1098 | 0.130 |
Why?
|
| Laryngeal Diseases | 1 | 1997 | 28 | 0.130 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 459 | 0.130 |
Why?
|
| Patient Admission | 1 | 2019 | 185 | 0.130 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1997 | 24 | 0.130 |
Why?
|
| Psychotherapy | 2 | 2018 | 248 | 0.130 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2017 | 32 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 457 | 0.130 |
Why?
|
| Data Mining | 1 | 2017 | 65 | 0.130 |
Why?
|
| Medical Records | 2 | 2012 | 175 | 0.130 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 47 | 0.130 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 26 | 0.130 |
Why?
|
| Connective Tissue Diseases | 1 | 1997 | 32 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2018 | 347 | 0.120 |
Why?
|
| Infant, Newborn | 8 | 2018 | 8523 | 0.120 |
Why?
|
| Intestinal Neoplasms | 1 | 1997 | 36 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2018 | 147 | 0.120 |
Why?
|
| Contraindications | 2 | 2013 | 76 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2017 | 234 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 372 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 726 | 0.120 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 51 | 0.120 |
Why?
|
| Menopause | 1 | 2017 | 86 | 0.120 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2017 | 31 | 0.120 |
Why?
|
| Musculoskeletal Diseases | 1 | 1997 | 53 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2018 | 307 | 0.120 |
Why?
|
| Mucous Membrane | 2 | 2012 | 93 | 0.120 |
Why?
|
| Tuberculin Test | 1 | 2017 | 119 | 0.120 |
Why?
|
| Immunotherapy | 2 | 2019 | 759 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 61 | 0.120 |
Why?
|
| Metabolome | 1 | 2019 | 324 | 0.120 |
Why?
|
| Lactams, Macrocyclic | 3 | 2022 | 33 | 0.120 |
Why?
|
| Hormones | 1 | 2017 | 162 | 0.120 |
Why?
|
| Anticonvulsants | 1 | 1999 | 362 | 0.120 |
Why?
|
| Tea | 1 | 2015 | 17 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 309 | 0.120 |
Why?
|
| Educational Status | 2 | 2015 | 276 | 0.120 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 85 | 0.120 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 75 | 0.120 |
Why?
|
| Regional Medical Programs | 1 | 2015 | 18 | 0.120 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 5 | 0.120 |
Why?
|
| Postoperative Complications | 3 | 2015 | 3113 | 0.120 |
Why?
|
| Cyclopropanes | 3 | 2022 | 67 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 62 | 0.120 |
Why?
|
| Herpes Simplex | 1 | 1996 | 58 | 0.120 |
Why?
|
| Cold Temperature | 1 | 2015 | 81 | 0.120 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 163 | 0.110 |
Why?
|
| Patient Acuity | 1 | 2015 | 66 | 0.110 |
Why?
|
| Paris | 1 | 2015 | 12 | 0.110 |
Why?
|
| Hot Temperature | 1 | 2015 | 141 | 0.110 |
Why?
|
| Program Evaluation | 2 | 2015 | 443 | 0.110 |
Why?
|
| Simvastatin | 1 | 2015 | 75 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2018 | 671 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 218 | 0.110 |
Why?
|
| Metabolomics | 1 | 2019 | 501 | 0.110 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 9 | 0.110 |
Why?
|
| Circadian Rhythm | 2 | 2017 | 316 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2002 | 899 | 0.110 |
Why?
|
| Colitis | 1 | 1996 | 164 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2009 | 1875 | 0.110 |
Why?
|
| Drug Therapy | 2 | 2013 | 84 | 0.110 |
Why?
|
| Reoperation | 1 | 2017 | 818 | 0.100 |
Why?
|
| Ribavirin | 2 | 2011 | 85 | 0.100 |
Why?
|
| Vaccination | 2 | 2010 | 1051 | 0.100 |
Why?
|
| Gastric Acid | 2 | 2018 | 53 | 0.100 |
Why?
|
| Birth Weight | 1 | 2015 | 345 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 2 | 2013 | 233 | 0.100 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2012 | 60 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2001 | 695 | 0.100 |
Why?
|
| Esophagectomy | 1 | 2014 | 70 | 0.100 |
Why?
|
| Etidronic Acid | 1 | 2013 | 10 | 0.100 |
Why?
|
| Infectious Disease Medicine | 1 | 2013 | 13 | 0.100 |
Why?
|
| Alendronate | 1 | 2013 | 22 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 222 | 0.100 |
Why?
|
| South America | 1 | 2013 | 45 | 0.100 |
Why?
|
| Intention | 1 | 2014 | 101 | 0.100 |
Why?
|
| Sulfonamides | 3 | 2022 | 297 | 0.100 |
Why?
|
| Middle East | 1 | 2013 | 36 | 0.100 |
Why?
|
| Bariatric Surgery | 1 | 2015 | 154 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2013 | 236 | 0.100 |
Why?
|
| Lung Diseases | 1 | 1997 | 396 | 0.100 |
Why?
|
| Intuition | 1 | 2013 | 5 | 0.100 |
Why?
|
| Asbestos | 1 | 2013 | 11 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2017 | 511 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2013 | 64 | 0.100 |
Why?
|
| Consensus | 3 | 2021 | 530 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2014 | 206 | 0.100 |
Why?
|
| Contrast Media | 2 | 2006 | 479 | 0.100 |
Why?
|
| Lysine | 1 | 2013 | 164 | 0.100 |
Why?
|
| Azathioprine | 1 | 2012 | 36 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2017 | 1623 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2021 | 304 | 0.090 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 11 | 0.090 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2012 | 7 | 0.090 |
Why?
|
| Intestinal Polyps | 2 | 2006 | 28 | 0.090 |
Why?
|
| Mercaptopurine | 1 | 2012 | 72 | 0.090 |
Why?
|
| Hepatitis B e Antigens | 1 | 2012 | 14 | 0.090 |
Why?
|
| Aflatoxin B1 | 1 | 2012 | 5 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 208 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 1456 | 0.090 |
Why?
|
| Health Care Costs | 2 | 2008 | 401 | 0.090 |
Why?
|
| Ferritins | 2 | 2022 | 106 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2012 | 247 | 0.090 |
Why?
|
| Gallstones | 1 | 2012 | 18 | 0.090 |
Why?
|
| Hospitals | 2 | 2025 | 437 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2013 | 731 | 0.090 |
Why?
|
| Choledochal Cyst | 1 | 2011 | 9 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 169 | 0.090 |
Why?
|
| Hemochromatosis Protein | 2 | 2022 | 22 | 0.090 |
Why?
|
| Analgesics | 1 | 2012 | 119 | 0.080 |
Why?
|
| Premature Birth | 1 | 2015 | 421 | 0.080 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 22 | 0.080 |
Why?
|
| Hepatitis A Antibodies | 1 | 2010 | 9 | 0.080 |
Why?
|
| Hepatitis B Antibodies | 1 | 2010 | 24 | 0.080 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2011 | 67 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 844 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2021 | 811 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 258 | 0.080 |
Why?
|
| Early Diagnosis | 2 | 2008 | 189 | 0.080 |
Why?
|
| Family | 1 | 2014 | 582 | 0.080 |
Why?
|
| Asia, Southeastern | 1 | 2010 | 22 | 0.080 |
Why?
|
| Health Policy | 1 | 2013 | 224 | 0.080 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2011 | 75 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 202 | 0.080 |
Why?
|
| Parasitic Diseases | 1 | 2011 | 60 | 0.080 |
Why?
|
| Calibration | 1 | 2010 | 92 | 0.080 |
Why?
|
| Science | 1 | 2010 | 36 | 0.080 |
Why?
|
| Methotrexate | 1 | 2012 | 339 | 0.080 |
Why?
|
| Pain | 2 | 2014 | 428 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2007 | 42 | 0.080 |
Why?
|
| Africa South of the Sahara | 1 | 2010 | 120 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2002 | 264 | 0.080 |
Why?
|
| Energy Intake | 2 | 2020 | 498 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2011 | 116 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2105 | 0.080 |
Why?
|
| Community Health Services | 1 | 2010 | 87 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 12 | 0.080 |
Why?
|
| Pressure | 2 | 2006 | 121 | 0.070 |
Why?
|
| Dietary Proteins | 1 | 2011 | 221 | 0.070 |
Why?
|
| Managed Care Programs | 1 | 2009 | 54 | 0.070 |
Why?
|
| Wine | 1 | 2009 | 15 | 0.070 |
Why?
|
| Peritoneum | 1 | 2009 | 34 | 0.070 |
Why?
|
| Paracentesis | 1 | 2009 | 20 | 0.070 |
Why?
|
| Virus Replication | 1 | 2012 | 607 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 704 | 0.070 |
Why?
|
| Health Maintenance Organizations | 1 | 2008 | 17 | 0.070 |
Why?
|
| Carbamates | 2 | 2019 | 63 | 0.070 |
Why?
|
| Medical Order Entry Systems | 1 | 2010 | 108 | 0.070 |
Why?
|
| Amides | 2 | 2019 | 82 | 0.070 |
Why?
|
| Heterozygote | 2 | 2022 | 720 | 0.070 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 70 | 0.070 |
Why?
|
| RNA, Viral | 1 | 2010 | 500 | 0.070 |
Why?
|
| Family Practice | 1 | 2008 | 83 | 0.070 |
Why?
|
| Colonoscopes | 1 | 2008 | 9 | 0.070 |
Why?
|
| Primary Prevention | 2 | 2016 | 179 | 0.070 |
Why?
|
| Enema | 2 | 2006 | 45 | 0.070 |
Why?
|
| Body Weight | 2 | 2016 | 984 | 0.070 |
Why?
|
| Immunization Schedule | 1 | 2008 | 111 | 0.070 |
Why?
|
| Finland | 1 | 2008 | 46 | 0.070 |
Why?
|
| Sample Size | 1 | 2008 | 84 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 25 | 0.070 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 50 | 0.070 |
Why?
|
| Ethanol | 1 | 2009 | 165 | 0.070 |
Why?
|
| Colonic Diseases | 1 | 2008 | 36 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 241 | 0.070 |
Why?
|
| Acute Disease | 2 | 2002 | 1147 | 0.070 |
Why?
|
| Ulcer | 2 | 1997 | 51 | 0.070 |
Why?
|
| Aging | 1 | 2015 | 1241 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 227 | 0.070 |
Why?
|
| California | 1 | 2007 | 126 | 0.070 |
Why?
|
| Keratin-20 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Body Composition | 2 | 2011 | 544 | 0.070 |
Why?
|
| Keratin-7 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Gastric Fundus | 1 | 2007 | 9 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2007 | 211 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 241 | 0.060 |
Why?
|
| Barium Sulfate | 1 | 2006 | 12 | 0.060 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 10 | 0.060 |
Why?
|
| Nausea | 1 | 2007 | 83 | 0.060 |
Why?
|
| Consumer Behavior | 1 | 2007 | 30 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2007 | 70 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 228 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 34 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 140 | 0.060 |
Why?
|
| Genes, cdc | 1 | 2006 | 23 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 679 | 0.060 |
Why?
|
| Monitoring, Ambulatory | 1 | 2006 | 56 | 0.060 |
Why?
|
| Health Promotion | 1 | 2010 | 412 | 0.060 |
Why?
|
| Prejudice | 1 | 2006 | 39 | 0.060 |
Why?
|
| Manometry | 1 | 2006 | 74 | 0.060 |
Why?
|
| Vomiting | 1 | 2007 | 104 | 0.060 |
Why?
|
| Risk Adjustment | 1 | 2006 | 55 | 0.060 |
Why?
|
| Dilatation | 1 | 2006 | 65 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 424 | 0.060 |
Why?
|
| Exanthema | 1 | 2007 | 72 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2026 | 125 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2007 | 218 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 216 | 0.060 |
Why?
|
| Body Height | 1 | 2006 | 194 | 0.060 |
Why?
|
| Lymphoma | 2 | 2014 | 328 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1402 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2007 | 163 | 0.060 |
Why?
|
| Estrogens | 1 | 2008 | 427 | 0.060 |
Why?
|
| Probability Theory | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cheese | 1 | 2025 | 8 | 0.060 |
Why?
|
| Psychological Tests | 1 | 2005 | 86 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2025 | 166 | 0.060 |
Why?
|
| Health Facility Size | 1 | 2005 | 5 | 0.060 |
Why?
|
| Yogurt | 1 | 2025 | 13 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 369 | 0.060 |
Why?
|
| Clarithromycin | 1 | 2025 | 133 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2005 | 87 | 0.060 |
Why?
|
| Metronidazole | 1 | 2025 | 161 | 0.060 |
Why?
|
| Diarrhea | 1 | 2007 | 315 | 0.050 |
Why?
|
| Appointments and Schedules | 2 | 2016 | 48 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2005 | 142 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2025 | 87 | 0.050 |
Why?
|
| Micronutrients | 1 | 2005 | 61 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 707 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1384 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 32 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 263 | 0.050 |
Why?
|
| Psychometrics | 2 | 2012 | 672 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2026 | 110 | 0.050 |
Why?
|
| Arizona | 1 | 2004 | 25 | 0.050 |
Why?
|
| Pedigree | 1 | 2008 | 1672 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 249 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2004 | 81 | 0.050 |
Why?
|
| Bilirubin | 1 | 2024 | 126 | 0.050 |
Why?
|
| Psychology | 1 | 2004 | 61 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1206 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2025 | 245 | 0.050 |
Why?
|
| Nizatidine | 1 | 2003 | 4 | 0.050 |
Why?
|
| Virginia | 1 | 2003 | 20 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 402 | 0.050 |
Why?
|
| Wales | 1 | 2002 | 7 | 0.050 |
Why?
|
| Aflatoxins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2002 | 18 | 0.050 |
Why?
|
| Phospholipases | 1 | 2022 | 9 | 0.050 |
Why?
|
| England | 1 | 2002 | 58 | 0.050 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2002 | 18 | 0.050 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2002 | 14 | 0.050 |
Why?
|
| Misoprostol | 1 | 2002 | 23 | 0.050 |
Why?
|
| Computer Graphics | 1 | 2002 | 39 | 0.050 |
Why?
|
| Cholelithiasis | 1 | 2002 | 16 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 792 | 0.050 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2022 | 47 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 87 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 89 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 290 | 0.050 |
Why?
|
| Homozygote | 2 | 2003 | 535 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2006 | 1448 | 0.040 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 18 | 0.040 |
Why?
|
| Hypertension, Portal | 1 | 2002 | 78 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 832 | 0.040 |
Why?
|
| Aminoglycosides | 1 | 2001 | 44 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1367 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2002 | 142 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 2009 | 0.040 |
Why?
|
| Benchmarking | 1 | 2021 | 135 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 305 | 0.040 |
Why?
|
| Sclerotherapy | 1 | 2000 | 36 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 289 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2020 | 31 | 0.040 |
Why?
|
| Oral Health | 1 | 2020 | 28 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 240 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 24 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 38 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 478 | 0.040 |
Why?
|
| Indonesia | 1 | 2020 | 21 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 269 | 0.040 |
Why?
|
| Laparoscopy | 2 | 2017 | 536 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2020 | 53 | 0.040 |
Why?
|
| Nutritive Value | 1 | 2020 | 84 | 0.040 |
Why?
|
| Nuclear Family | 1 | 2000 | 50 | 0.040 |
Why?
|
| Decision Trees | 1 | 2000 | 57 | 0.040 |
Why?
|
| Biodiversity | 1 | 2020 | 72 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 143 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 374 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1046 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2004 | 687 | 0.040 |
Why?
|
| Creatinine | 1 | 2001 | 396 | 0.040 |
Why?
|
| Anilides | 1 | 2019 | 52 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 23 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2019 | 5 | 0.040 |
Why?
|
| Mutation | 3 | 2022 | 6088 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 144 | 0.040 |
Why?
|
| Health Behavior | 1 | 2022 | 388 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 278 | 0.040 |
Why?
|
| Heart Failure | 2 | 2016 | 2328 | 0.040 |
Why?
|
| Developed Countries | 1 | 1999 | 43 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 310 | 0.040 |
Why?
|
| Stroke | 1 | 2007 | 1056 | 0.040 |
Why?
|
| Africa | 1 | 1999 | 140 | 0.040 |
Why?
|
| Point Mutation | 1 | 2000 | 332 | 0.040 |
Why?
|
| Quinolines | 1 | 2019 | 114 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 4 | 0.030 |
Why?
|
| Hong Kong | 1 | 2018 | 21 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2001 | 324 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 706 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 209 | 0.030 |
Why?
|
| beta Catenin | 1 | 2019 | 198 | 0.030 |
Why?
|
| Health Resources | 1 | 1999 | 127 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2018 | 31 | 0.030 |
Why?
|
| Granulation Tissue | 1 | 1997 | 12 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 112 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 480 | 0.030 |
Why?
|
| Paranasal Sinus Diseases | 1 | 1997 | 13 | 0.030 |
Why?
|
| Mycobacterium avium Complex | 1 | 1997 | 20 | 0.030 |
Why?
|
| Pharyngeal Diseases | 1 | 1997 | 17 | 0.030 |
Why?
|
| Adiponectin | 1 | 2018 | 122 | 0.030 |
Why?
|
| Health Personnel | 1 | 2022 | 550 | 0.030 |
Why?
|
| Aftercare | 1 | 2018 | 151 | 0.030 |
Why?
|
| Software | 1 | 2022 | 730 | 0.030 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 7 | 0.030 |
Why?
|
| Adalimumab | 1 | 2017 | 21 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 285 | 0.030 |
Why?
|
| Iron | 1 | 2000 | 305 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 383 | 0.030 |
Why?
|
| Nadolol | 1 | 2016 | 12 | 0.030 |
Why?
|
| Infliximab | 1 | 2017 | 61 | 0.030 |
Why?
|
| Insulin | 1 | 2021 | 1140 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 40 | 0.030 |
Why?
|
| Animals | 3 | 2025 | 33781 | 0.030 |
Why?
|
| Military Personnel | 1 | 1999 | 209 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1997 | 356 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 959 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 133 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2018 | 178 | 0.030 |
Why?
|
| Arthritis | 1 | 1997 | 83 | 0.030 |
Why?
|
| Propranolol | 1 | 2016 | 111 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 139 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 253 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1997 | 348 | 0.030 |
Why?
|
| Phosphates | 1 | 1996 | 111 | 0.030 |
Why?
|
| Health Services | 1 | 2016 | 69 | 0.030 |
Why?
|
| Inappropriate Prescribing | 1 | 2015 | 40 | 0.030 |
Why?
|
| Scleroderma, Systemic | 1 | 1997 | 117 | 0.030 |
Why?
|
| Drinking | 1 | 2015 | 27 | 0.030 |
Why?
|
| Satiation | 1 | 2015 | 27 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 565 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2015 | 78 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 1694 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 611 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 861 | 0.030 |
Why?
|
| Polyethylene Glycols | 2 | 2011 | 232 | 0.030 |
Why?
|
| Seizures | 1 | 1999 | 874 | 0.020 |
Why?
|
| Heart Rate | 1 | 2016 | 576 | 0.020 |
Why?
|
| Macrophages | 1 | 1997 | 660 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 142 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 2014 | 77 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2014 | 267 | 0.020 |
Why?
|
| Walking | 1 | 2015 | 227 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 77 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2019 | 948 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2014 | 449 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2013 | 139 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2012 | 45 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2015 | 846 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 112 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 224 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 202 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 436 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2011 | 140 | 0.020 |
Why?
|
| Carrier State | 1 | 2010 | 81 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 643 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 288 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 889 | 0.020 |
Why?
|
| Trachea | 1 | 2011 | 206 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 502 | 0.020 |
Why?
|
| Illinois | 1 | 2008 | 17 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2012 | 449 | 0.020 |
Why?
|
| Medicaid | 1 | 2011 | 251 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 1319 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 298 | 0.020 |
Why?
|
| Focus Groups | 1 | 2007 | 231 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2010 | 714 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 775 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2008 | 284 | 0.010 |
Why?
|
| Hypoxia | 1 | 2007 | 247 | 0.010 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2007 | 151 | 0.010 |
Why?
|
| Graft Survival | 1 | 2005 | 460 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2005 | 558 | 0.010 |
Why?
|
| Egypt | 1 | 2001 | 30 | 0.010 |
Why?
|
| Hepatitis C Antibodies | 1 | 2001 | 27 | 0.010 |
Why?
|
| Schistosomiasis mansoni | 1 | 2001 | 24 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 18195 | 0.010 |
Why?
|
| Antibodies, Helminth | 1 | 2001 | 131 | 0.010 |
Why?
|
| Pediatrics | 1 | 2008 | 1243 | 0.010 |
Why?
|
| Duodenal Ulcer | 1 | 1998 | 127 | 0.010 |
Why?
|
| Solutions | 1 | 1996 | 50 | 0.010 |
Why?
|
| Electrolytes | 1 | 1996 | 59 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 560 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1996 | 707 | 0.010 |
Why?
|